New surveillance data from the Vaccine Safety Datalink confirm a small but statistically significant increased risk for Guillain-Barré syndrome (GBS) in the 3 weeks after receipt of the Janssen/Johnson & Johnson COVID-19 vaccine. The Janssen vaccine (Ad26.COV2.S) is a replication-incompetent adenoviral vector vaccine. The data show no increased risk of […]